{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:14:39Z","timestamp":1793830479527,"version":"4.6.1"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2011,9,13]],"date-time":"2011-09-13T00:00:00Z","timestamp":1315872000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2011,11]]},"DOI":"10.1007\/s00280-011-1737-2","type":"journal-article","created":{"date-parts":[[2011,9,12]],"date-time":"2011-09-12T18:05:50Z","timestamp":1315850750000},"page":"1099-1109","source":"Crossref","is-referenced-by-count":85,"title":["Drug-induced interstitial lung disease in tyrosine kinase inhibitor therapy for non-small cell lung cancer: a review on current insight"],"prefix":"10.1007","volume":"68","author":[{"given":"Ji Hye","family":"Min","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ho Yun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoyeong","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myung-Ju","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keunchil","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Man Pyo","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung Soo","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,9,13]]},"reference":[{"issue":"10","key":"1737_CR1","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa0810699","volume":"361","author":"TS Mok","year":"2009","unstructured":"Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang JJ, Chewaskulyong B, Jiang H, Duffield EL, Watkins CL, Armour AA, Fukuoka M (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361(10):947\u2013957","journal-title":"N Engl J Med"},{"issue":"25","key":"1737_CR2","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1056\/NEJMoa0909530","volume":"362","author":"M Maemondo","year":"2010","unstructured":"Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Ogura T, Ando M, Miyazawa H, Tanaka T, Saijo Y, Hagiwara K, Morita S, Nukiwa T (2010) Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362(25):2380\u20132388","journal-title":"N Engl J Med"},{"issue":"9352","key":"1737_CR3","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0140-6736(03)12190-3","volume":"361","author":"A Inoue","year":"2003","unstructured":"Inoue A, Saijo Y, Maemondo M, Gomi K, Tokue Y, Kimura Y, Ebina M, Kikuchi T, Moriya T, Nukiwa T (2003) Severe acute interstitial pneumonia and gefitinib. Lancet 361(9352):137\u2013139","journal-title":"Lancet"},{"issue":"1","key":"1737_CR4","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/1471-2407-7-150","volume":"7","author":"D Makris","year":"2007","unstructured":"Makris D, Scherpereel A, Copin M, Colin G, Brun L, Lafitte J, Marquette C (2007) Fatal interstitial lung disease associated with oral erlotinib therapy for lung cancer. BMC cancer 7(1):150","journal-title":"BMC cancer"},{"issue":"3","key":"1737_CR5","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1378\/chest.07-0050","volume":"132","author":"V Liu","year":"2007","unstructured":"Liu V, White D, Zakowski M, Travis W, Kris M, Ginsberg M, Miller V, Azzoli C (2007) Pulmonary toxicity associated with Erlotinib*. Chest 132(3):1042\u20131044","journal-title":"Chest"},{"issue":"16","key":"1737_CR6","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1200\/JCO.2005.04.9866","volume":"24","author":"M Ando","year":"2006","unstructured":"Ando M, Okamoto I, Yamamoto N, Takeda K, Tamura K, Seto T, Ariyoshi Y, Fukuoka M (2006) Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 24(16):2549\u20132556","journal-title":"J Clin Oncol"},{"issue":"5","key":"1737_CR7","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/00130404-200509000-00010","volume":"11","author":"K Hotta","year":"2005","unstructured":"Hotta K, Kiura K, Tabata M, Harita S, Gemba K, Yonei T, Bessho A, Maeda T, Moritaka T, Shibayama T (2005) Interstitial lung disease in Japanese patients with non-small cell lung cancer receiving gefitinib: an analysis of risk factors and treatment outcomes in Okayama Lung Cancer Study Group. Cancer J 11(5):417\u2013424","journal-title":"Cancer J"},{"issue":"2","key":"1737_CR8","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/JTO.0b013e3181ca12e0","volume":"5","author":"K Hotta","year":"2010","unstructured":"Hotta K, Kiura K, Takigawa N, Yoshioka H, Harita S, Kuyama S, Yonei T, Fujiwara K, Maeda T, Aoe K, Ueoka H, Kamei H, Umemura S, Moritaka T, Segawa Y, Kawai H, Bessho A, Kato K, Tabata M, Tanimoto M (2010) Comparison of the incidence and pattern of interstitial lung disease during erlotinib and gefitinib treatment in Japanese patients with non-small cell lung cancer: the Okayama Lung Cancer Study Group Experience. J Thorac Oncol 5(2):179\u2013184","journal-title":"J Thorac Oncol"},{"issue":"1","key":"1737_CR9","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.lungcan.2004.01.010","volume":"45","author":"T Takano","year":"2004","unstructured":"Takano T, Ohe Y, Kusumoto M, Tateishi U, Yamamoto S, Nokihara H, Yamamoto N, Sekine I, Kunitoh H, Tamura T (2004) Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib. Lung Cancer 45(1):93\u2013104","journal-title":"Lung Cancer"},{"key":"1737_CR10","doi-asserted-by":"crossref","unstructured":"Seto T, Yamamoto N (2004) Interstitial lung diseases (ILD) induced by gefitinib in patients with advanced non-small cell lung cancer (NSCLC): results of a West Japan Thoracic Oncology Group (WJTOG) epidemiological survey. In: ASCO Annual Meeting Proceedings (Post-Meeting Edition), J Clin Oncol vol 22, no 14S, p 7064, July 15 2004","DOI":"10.1200\/jco.2004.22.90140.7064"},{"issue":"1","key":"1737_CR11","first-page":"100","volume":"33","author":"C Chou","year":"2010","unstructured":"Chou C, Ko H, Wang C, Yu C, Kuo H, Huang C (2010) Erlotinib-associated near-fatal interstitial pneumonitis in a patient with relapsed lung adenocarcinoma. Chang Gung Med J 33(1):100\u2013105","journal-title":"Chang Gung Med J"},{"issue":"3","key":"1737_CR12","first-page":"167","volume":"14","author":"B Vahid","year":"2007","unstructured":"Vahid B, Esmaili A (2007) Erlotinib-associated acute pneumonitis: report of two cases. Can Respir J\u00a0J Can Thorac Soc 14(3):167\u2013170","journal-title":"Can Respir J\u00a0J Can Thorac Soc"},{"key":"1737_CR13","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/1757-1626-3-59","volume":"3","author":"Y Del Castillo","year":"2010","unstructured":"Del Castillo Y, Espinosa P, Bodi F, Alcega R, Munoz E, Rabasso C, Castander D (2010) Interstitial lung disease associated to erlotinib treatment: a case report. Cases J 3:59","journal-title":"Cases J"},{"issue":"8","key":"1737_CR14","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1097\/JTO.0b013e3181a94a2f","volume":"4","author":"K Tsujino","year":"2009","unstructured":"Tsujino K, Kawaguchi T, Kubo A, Aono N, Nakao K, Koh Y, Tachibana K, Isa S, Takada M, Kurata T (2009) Response rate is associated with prolonged survival in patients with advanced non-small cell lung cancer treated with gefitinib or erlotinib. J Thorac Oncol 4(8):994\u20131001","journal-title":"J Thorac Oncol"},{"issue":"22","key":"1737_CR15","doi-asserted-by":"crossref","first-page":"4442","DOI":"10.1200\/JCO.2004.07.960","volume":"22","author":"M Ratain","year":"2004","unstructured":"Ratain M, Eckhardt S (2004) Phase II studies of modern drugs directed against new targets: if you are fazed, too, then resist RECIST. J Clin Oncol 22(22):4442\u20134445","journal-title":"J Clin Oncol"},{"issue":"2","key":"1737_CR16","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1378\/chest.07-0851","volume":"133","author":"B Vahid","year":"2008","unstructured":"Vahid B, Marik P (2008) Pulmonary complications of novel antineoplastic agents for solid tumors. Chest 133(2):528\u2013538","journal-title":"Chest"},{"key":"1737_CR17","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1038\/sj.bjc.6602063","volume":"91","author":"P Camus","year":"2004","unstructured":"Camus P, Kudoh S, Ebina M (2004) Interstitial lung disease associated with drug therapy. Br J Cancer 91:S18\u2013S23","journal-title":"Br J Cancer"},{"key":"1737_CR18","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1038\/sj.bjc.6602064","volume":"91","author":"N Muller","year":"2004","unstructured":"Muller N, White D, Jiang H, Gemma A (2004) Diagnosis and management of drug-associated interstitial lung disease. Br J Cancer 91:S24\u2013S30","journal-title":"Br J Cancer"},{"issue":"4","key":"1737_CR19","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1634\/theoncologist.8-4-303","volume":"8","author":"MH Cohen","year":"2003","unstructured":"Cohen MH, Williams GA, Sridhara R, Chen G, Pazdur R (2003) FDA drug approval summary: Gefitinib (ZD1839)(Iressa (R)) tablets. Oncologist 8(4):303\u2013306","journal-title":"Oncologist"},{"issue":"1B","key":"1737_CR20","first-page":"415","volume":"25","author":"K Aoe","year":"2005","unstructured":"Aoe K, Hiraki A, Murakami T, Maeda T, Umemori Y, Katayama H, Eda R, Takeyama H (2005) Sudden onset of interstitial lung disease induced by gefitinib in a lung cancer patient with multiple drug allergy. Anticancer Res 25(1B):415\u2013418","journal-title":"Anticancer Res"},{"issue":"2","key":"1737_CR21","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.lungcan.2006.02.002","volume":"52","author":"M Endo","year":"2006","unstructured":"Endo M, Johkoh T, Kimura K, Yamamoto N (2006) Imaging of gefitinib-related interstitial lung disease: multi-institutional analysis by the West Japan Thoracic Oncology Group. Lung Cancer 52(2):135\u2013140","journal-title":"Lung Cancer"},{"issue":"3","key":"1737_CR22","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/j.1752-699X.2008.00115.x","volume":"3","author":"S Um","year":"2009","unstructured":"Um S, Lee S, Yang D, Son C, Roh M, Kim K, Lee K, Choi P (2009) Fatal interstitial lung disease after erlotinib administration in a patient with radiation fibrosis. Clin Respir J 3(3):181\u2013184","journal-title":"Clin Respir J"},{"issue":"10","key":"1737_CR23","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1200\/JCO.2005.04.055","volume":"23","author":"N Nagaria","year":"2005","unstructured":"Nagaria N, Cogswell J, Choe J, Kasimis B (2005) Side effects and good effects from new chemotherapeutic agents: case 1. Gefitinib-induced interstitial fibrosis. J Clin Oncol 23(10):2423\u20132424","journal-title":"J Clin Oncol"},{"key":"1737_CR24","first-page":"667s","volume":"23","author":"M Nakagawa","year":"2005","unstructured":"Nakagawa M, Teramukai S, Tada H (2005) Hypoalbumia as a risk factor of interstitinal lung disease (ILD) during gefitinib treatment in patients with non-small cell lung cancer (NSCLC): a JMTO study. Proc ASCO 23:667s (Abstract# 7190)","journal-title":"Proc ASCO"},{"issue":"4","key":"1737_CR25","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1158\/1078-0432.CCR-03-0564","volume":"10","author":"M Cohen","year":"2004","unstructured":"Cohen M, Williams G, Sridhara R, Chen G, McGuinn W, Morse D, Abraham S, Rahman A, Liang C, Lostritto R (2004) United States food and drug administration drug approval summary. Clin Cancer Res 10(4):1212\u20131218","journal-title":"Clin Cancer Res"},{"issue":"7","key":"1737_CR26","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1634\/theoncologist.10-7-461","volume":"10","author":"M Cohen","year":"2005","unstructured":"Cohen M, Johnson J, Chen Y, Sridhara R, Pazdur R (2005) (Tarceva (R)) tablets. Oncologist 10(7):461\u2013466","journal-title":"Oncologist"},{"issue":"25","key":"1737_CR27","doi-asserted-by":"crossref","first-page":"5892","DOI":"10.1200\/JCO.2005.02.840","volume":"23","author":"R Herbst","year":"2005","unstructured":"Herbst R, Prager D, Hermann R, Fehrenbacher L, Johnson B, Sandler A, Kris M, Tran H, Klein P, Li X (2005) TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 23(25):5892\u20135899","journal-title":"J Clin Oncol"},{"issue":"1","key":"1737_CR28","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1272\/jnms.76.4","volume":"76","author":"A Gemma","year":"2009","unstructured":"Gemma A (2009) Drug-induced interstitial lung diseases associated with molecular-targeted anticancer agents. J Nippon Med School 76(1):4\u20138","journal-title":"J Nippon Med School"},{"issue":"3","key":"1737_CR29","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.lungcan.2009.10.012","volume":"67","author":"WC Dempke","year":"2010","unstructured":"Dempke WC, Suto T, Reck M (2010) Targeted therapies for non-small cell lung cancer. Lung Cancer 67(3):257\u2013274","journal-title":"Lung Cancer"},{"issue":"10","key":"1737_CR30","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1097\/JTO.0b013e318187220f","volume":"3","author":"P Wheatley-Price","year":"2008","unstructured":"Wheatley-Price P, Shepherd F (2008) Targeting angiogenesis in the treatment of lung cancer. J Thorac Oncol 3(10):1173\u20131184","journal-title":"J Thorac Oncol"},{"issue":"2","key":"1737_CR31","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.lungcan.2009.10.007","volume":"67","author":"S Ide","year":"2010","unstructured":"Ide S, Soda H, Hakariya T, Takemoto S, Ishimoto H, Tomari S, Sawai T, Nagashima S, Furukawa M, Nakamura Y (2010) Interstitial pneumonia probably associated with sorafenib treatment: an alert of an adverse event. Lung Cancer 67(2):248\u2013250","journal-title":"Lung Cancer"},{"issue":"1","key":"1737_CR32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/thx.37.1.1","volume":"37","author":"BA Keogh","year":"1982","unstructured":"Keogh BA, Crystal RG (1982) Alveolitis: the key to the interstitial lung disorders. Thorax 37(1):1\u201310","journal-title":"Thorax"},{"issue":"2","key":"1737_CR33","doi-asserted-by":"crossref","first-page":"136","DOI":"10.7326\/0003-4819-134-2-200101160-00015","volume":"134","author":"M Selman","year":"2001","unstructured":"Selman M, King TE, Pardo A (2001) Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med 134(2):136\u2013151","journal-title":"Ann Intern Med"},{"issue":"16","key":"1737_CR34","first-page":"5054","volume":"63","author":"H Suzuki","year":"2003","unstructured":"Suzuki H, Aoshiba K, Yokohori N, Nagai A (2003) Epidermal growth factor receptor tyrosine kinase inhibition augments a murine model of pulmonary fibrosis. Cancer Res 63(16):5054\u20135059","journal-title":"Cancer Res"},{"key":"1737_CR35","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1038\/sj.bjc.6602065","volume":"91","author":"T Higenbottam","year":"2004","unstructured":"Higenbottam T, Kuwano K, Nemery B, Fujita Y (2004) Understanding the mechanisms of drug-associated interstitial lung disease. Br J Cancer 91:S31\u2013S37","journal-title":"Br J Cancer"},{"issue":"12","key":"1737_CR36","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1097\/01.LAB.0000045084.81853.76","volume":"82","author":"K Kuwano","year":"2002","unstructured":"Kuwano K, Hagimoto N, Maeyama T, Fujita M, Yoshimi M, Inoshima I, Nakashima N, Hamada N, Watanabe K, Hara N (2002) Mitochondria-mediated apoptosis of lung epithelial cells in idiopathic interstitial pneumonias. Lab Invest 82(12):1695\u20131706","journal-title":"Lab Invest"},{"issue":"3","key":"1737_CR37","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1159\/000196329","volume":"61","author":"S Aida","year":"1994","unstructured":"Aida S, Tamai S, Sekiguchi S, Shimizu N (1994) Distribution of epidermal growth factor and epidermal growth factor receptor in human lung: immunohistochemical and immunoelectron-microscopic studies. Respiration 61(3):161\u2013166","journal-title":"Respiration"},{"issue":"9","key":"1737_CR38","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1097\/JTO.0b013e3181e9dbb9","volume":"5","author":"J Ryu","year":"2010","unstructured":"Ryu J (2010) Chemotherapy-induced pulmonary toxicity in lung cancer patients. J Thorac Oncol 5(9):1313\u20131314","journal-title":"J Thorac Oncol"},{"issue":"5","key":"1737_CR39","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1148\/radiographics.20.5.g00se081245","volume":"20","author":"SE Rossi","year":"2000","unstructured":"Rossi SE, Erasmus JJ, McAdams HP, Sporn TA, Goodman PC (2000) Pulmonary drug toxicity: radiologic and pathologic manifestations. Radiographics 20(5):1245\u20131259","journal-title":"Radiographics"},{"issue":"3","key":"1737_CR40","doi-asserted-by":"crossref","first-page":"230","DOI":"10.3109\/02841859409172373","volume":"35","author":"M Tagliabue","year":"1994","unstructured":"Tagliabue M, Casella T, Zincone G, Fumagalli R, Salvini E (1994) CT and chest radiography in the evaluation of adult respiratory distress syndrome. Acta Radiol 35(3):230\u2013234","journal-title":"Acta Radiol"},{"issue":"3","key":"1737_CR41","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1148\/radiol.2462070712","volume":"246","author":"D Hansell","year":"2008","unstructured":"Hansell D, Bankier A, MacMahon H, McLoud T, Muller N, Remy J (2008) Fleischner society: glossary of terms for thoracic imaging1. Radiology 246(3):697\u2013722","journal-title":"Radiology"},{"issue":"1","key":"1737_CR42","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1148\/radiol.2361031674","volume":"236","author":"D Lynch","year":"2005","unstructured":"Lynch D, Travis W, Muller N, Galvin J, Hansell D, Grenier P, King T Jr (2005) Idiopathic interstitial pneumonias: CT features1. Radiology 236(1):10\u201321","journal-title":"Radiology"},{"issue":"11","key":"1737_CR43","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1164\/rccm.200301-053SO","volume":"168","author":"J Ryu","year":"2003","unstructured":"Ryu J, Myers J, Swensen S (2003) Bronchiolar disorders. Am J Respir Crit Care Med 168(11):1277\u20131292","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"1737_CR44","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1513\/pats.200512-124JH","volume":"3","author":"DW Visscher","year":"2006","unstructured":"Visscher DW, Myers JL (2006) Bronchiolitis: the pathologist\u2019s perspective. Proc Am Thorac Soc 3(1):41\u201347","journal-title":"Proc Am Thorac Soc"},{"issue":"1","key":"1737_CR45","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/01.rti.0000203940.05147.7b","volume":"21","author":"J Dodd","year":"2006","unstructured":"Dodd J, Lee K, Johkoh T, Muller N (2006) Drug-associated organizing pneumonia: high-resolution CT findings in 9 patients. J Thorac Imaging 21(1):22\u201326","journal-title":"J Thorac Imaging"},{"issue":"2","key":"1737_CR46","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1053\/j.sult.2006.01.001","volume":"27","author":"C Isabela","year":"2006","unstructured":"Isabela C, Silva S, Muller N (2006) Drug-induced lung diseases: most common reaction patterns and corresponding high-resolution CT manifestations. Semin Ultrasound CT MR 27(2):111\u2013116","journal-title":"Semin Ultrasound CT MR"},{"issue":"4","key":"1737_CR47","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1164\/ajrccm.157.4.9707039","volume":"157","author":"A Katzenstein","year":"1998","unstructured":"Katzenstein A, Myers J (1998) Idiopathic pulmonary fibrosis. Clinical relevance of pathologic classification. Am J Respir Crit Care Med 157(4):1301\u20131315","journal-title":"Am J Respir Crit Care Med"},{"key":"1737_CR48","volume-title":"Diseases of the lung: radiologic and pathologic correlations","author":"N Muller","year":"2003","unstructured":"Muller N, Fraser R, Lee K, Johkoh T (2003) Diseases of the lung: radiologic and pathologic correlations. Lippincott Williams & Wilkins, Philadelphia"},{"issue":"9","key":"1737_CR49","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1097\/JTO.0b013e3181e369a8","volume":"5","author":"K Yoh","year":"2010","unstructured":"Yoh K, Kenmotsu H, Yamaguchi Y, Kubota K, Ohmatsu H, Goto K, Niho S, Ohe Y, Saijo N, Nishiwaki Y (2010) Severe interstitial lung disease associated with amrubicin treatment. J Thorac Oncol 5(9):1435\u20131438","journal-title":"J Thorac Oncol"},{"issue":"6","key":"1737_CR50","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1097\/JTO.0b013e318060d329","volume":"2","author":"KY Yoneda","year":"2007","unstructured":"Yoneda KY, Shelton DK, Beckett LA, Gandara DR (2007) Independent review of interstitial lung disease associated with death in TRIBUTE (paclitaxel and carboplatin with or without concurrent erlotinib) in advanced non-small cell lung cancer. J Thorac Oncol 2(6):537\u2013543","journal-title":"J Thorac Oncol"},{"issue":"5","key":"1737_CR51","doi-asserted-by":"crossref","first-page":"445","DOI":"10.4046\/trd.2009.67.5.445","volume":"67","author":"S Park","year":"2009","unstructured":"Park S, Kim A, Park J, Shin C, Nam H, Kim L, Cho J, Ryu J, Kwak S (2009) Recurrent erlotinib-induced interstitial lung disease on non-small cell lung cancer. Tuberc Respir Dis 67(5):445\u2013448","journal-title":"Tuberc Respir Dis"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-011-1737-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-011-1737-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-011-1737-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,4]],"date-time":"2021-12-04T13:03:05Z","timestamp":1638622985000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-011-1737-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9,13]]},"references-count":51,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011,11]]}},"alternative-id":["1737"],"URL":"https:\/\/doi.org\/10.1007\/s00280-011-1737-2","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,9,13]]}}}